XML 155 R140.htm IDEA: XBRL DOCUMENT
v3.24.0.1

SEGMENT INFORMATION - Revenues by Product Category (Details) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 USD ($) product | Dec. 31, 2022 USD ($) product | Dec. 31, 2021 USD ($) product
Revenue from External Customer [Line Items] |  |  |
Number of products represented of total revenue | product | 10 | 10 | 10
Revenues | $ 8,757 | $ 8,124 | $ 8,434
Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 3,909 | 3,642 | 3,743
Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,997 | 1,872 | 1,903
OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,797 | 1,619 | 1,538
Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 960 | 892 | 1,144
Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 94 | 99 | 106
Salix |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 2,250 | 2,090 | 2,074
Salix | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 2,251 | 2,090 | 2,066
Salix | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | (1) | 0 | 8
International |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,071 | 988 | 1,166
International | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 250 | 258 | 260
International | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
International | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 179 | 151 | 136
International | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 588 | 527 | 723
International | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 54 | 52 | 47
Solta Medical |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 347 | 300 | 308
Solta Medical | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Solta Medical | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 347 | 300 | 308
Solta Medical | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Solta Medical | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Solta Medical | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Diversified |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 943 | 978 | 1,121
Diversified | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 790 | 826 | 924
Diversified | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Diversified | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 7 | 7 | 7
Diversified | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 120 | 120 | 167
Diversified | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 26 | 25 | 23
Bausch + Lomb |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 4,146 | 3,768 | 3,765
Bausch + Lomb | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 618 | 468 | 493
Bausch + Lomb | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,650 | 1,572 | 1,595
Bausch + Lomb | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,611 | 1,461 | 1,395
Bausch + Lomb | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 252 | 245 | 254
Bausch + Lomb | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | $ 15 | $ 22 | $ 28
Revenues | Product Concentration Risk | Customer, Top Ten Products |  |  |
Revenue from External Customer [Line Items] |  |  |
Concentration risk, percentage | 48.00% | 49.00% | 43.00%

X
- Definition Concentration Risk, Number Of Products + References No definition available. + Details
Name: | bhc_ConcentrationRiskNumberOfProducts
Namespace Prefix: | bhc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_DeviceProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OtherRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |